Standard Biotools Inc.
LAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001162194
In the last 90 days, Standard Biotools Inc. insiders filed 1 open-market purchase and 0 sales; 143 institutions reported holding it in 13F filings for Q2 2026, worth $243.6M in total; Viking Global Investors is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:12 AM ET
Revenue flow, Q3 FY2026
Where the revenue went in Q3 FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net income for Q3 FY2026: $13.5M (69.6% of revenue).
Income statement
Each column is one quarter, newest first.
| Line item | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | – | Aug 5, 2026 | May 5, 2026 | Jan 8, 2026 | Nov 4, 2025 | Aug 11, 2025 | May 6, 2025 | Jan 13, 2025 |
| Revenue | $19.4M | $20.1M | $21.1M | $23.8M† | $19.6M | $21.8M | $40.8M | $46.7M† |
| Cost of revenue | $8.56M | $9.57M | $9.84M | $12.4M† | $10.1M | $11.1M | $21.1M | $24.8M† |
| Gross profit | $10.8M | $10.5M | $11.3M | $11.4M† | $9.48M | $10.6M | $19.7M | $21.9M† |
| Operating expenses | $30.6M | $35.9M | $23.8M | $36.0M† | $42.4M | $36.3M | $52.7M | $54.7M† |
| Research and development | $2.08M | $1.98M | $2.12M | $7.97M† | $6.36M | $6.22M | $11.3M | $14.1M† |
| Selling, general and administrative | $16.8M | $16.4M | $18.6M | $25.3M† | $26.6M | $28.1M | $38.7M | $37.6M† |
| Operating income | -$19.8M | -$25.4M | -$12.5M | -$24.6M† | -$32.9M | -$25.7M | -$33.0M | -$32.8M† |
| Income tax | $27.0K | $90.0K | $11.0K | -$35.9M† | -$1.22M | -$609.0K | -$151.0K | $272.0K† |
| Net income | $13.5M | -$26.8M | $127.1M | $19.3M† | -$34.7M | -$33.5M | -$26.0M | -$34.1M† |
| EPS, basic | $0.03 | $-0.07 | $0.33 | – | $-0.09 | $-0.09 | $-0.07 | – |
| EPS, diluted | $0.03 | $-0.07 | $0.33 | – | $-0.09 | $-0.09 | $-0.07 | – |
| Weighted shares, basic | 393.6M | 390.9M | 388.2M | – | 382.6M | 380.5M | 378.2M | – |
| Weighted shares, diluted | 393.6M | 390.9M | 388.2M | – | 382.6M | 380.5M | 378.2M | – |
| Margins and growth | ||||||||
| Gross margin | 55.9% | 52.4% | 53.5% | 47.8% | 48.5% | 48.8% | 48.4% | 46.9% |
| Operating margin | -102.0% | -126.3% | -59.1% | -103.6% | -168.5% | -118.1% | -80.8% | -70.2% |
| Net margin | 69.6% | -133.1% | 600.9% | 81.0% | -177.4% | -153.7% | -63.8% | -72.9% |
| Revenue growth, year over year | −0.9% | −7.6% | −48.2% | −49.1% | −56.5% | −41.5% | −10.4% | +65.7% |
Balance sheet
Each column is one quarter, newest first.
| Line item | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | – | Aug 5, 2026 | May 5, 2026 | Jan 8, 2026 | Nov 4, 2025 | Aug 11, 2025 | May 6, 2025 | Jan 13, 2025 |
| Cash and equivalents | $267.5M | $270.0M | $265.8M | $120.9M | $129.4M | $158.6M | $150.9M | $166.7M |
| Accounts receivable | $13.0M | $15.7M | $16.6M | $13.4M | $13.5M | $14.6M | $35.5M | $33.6M |
| Inventory | $17.6M | $17.1M | $18.6M | $20.0M | $25.4M | $24.2M | $42.1M | $40.7M |
| Total current assets | $497.3M | $516.9M | $521.5M | $454.3M | $472.4M | $506.0M | $344.0M | $375.9M |
| Property, plant and equipment | $13.2M | $15.3M | $17.1M | $19.3M | $20.7M | $22.7M | $43.6M | $42.6M |
| Goodwill | – | – | – | – | – | – | $111.7M | $111.3M |
| Intangible assets | – | – | – | – | – | – | $28.1M | $29.0M |
| Total assets | $635.3M | $627.2M | $639.1M | $567.8M | $539.6M | $557.0M | $579.6M | $612.3M |
| Accounts payable | $3.45M | $9.55M | $8.01M | $5.41M | $6.62M | $7.33M | $11.8M | $12.3M |
| Total current liabilities | $51.0M | $56.8M | $42.2M | $108.3M | $108.0M | $98.0M | $56.2M | $65.9M |
| Long-term debt | – | – | – | – | – | – | – | $299.0K |
| Total liabilities | $79.6M | $87.2M | $78.0M | $143.5M | $140.0M | $132.4M | $125.0M | $140.6M |
| Shareholders' equity | $555.8M | $540.0M | $561.1M | $424.3M | $399.7M | $424.5M | $454.6M | $471.7M |
Cash flow statement
Each column is one quarter, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | Q3 FY2026† | Q2 FY2026† | Q1 FY2026 | Q4 FY2025† | Q3 FY2025† | Q2 FY2025† | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | – | Aug 5, 2026 | May 5, 2026 | Jan 8, 2026 | Nov 4, 2025 | Aug 11, 2025 | May 6, 2025 | Jan 13, 2025 |
| Operating cash flow | -$6.16M† | -$10.3M† | -$46.6M | -$1.19M† | -$22.2M† | -$20.7M† | -$30.3M | -$14.1M† |
| Capital expenditures | $0† | $344.0K† | $570.0K | $476.0K† | $886.0K† | $1.89M† | $5.05M | $3.38M† |
| Free cash flow | -$6.16M | -$10.7M | -$47.2M | -$1.67M | -$23.1M | -$22.6M | -$35.3M | -$17.4M |
| Depreciation and amortization | $1.20M† | $1.27M† | $1.41M | $1.29M† | $1.52M† | $3.18M† | $3.27M | $2.90M† |
| Stock-based compensation | $3.72M† | $4.05M† | $8.82M | $5.74M† | $8.47M† | $6.39M† | $9.01M | $7.47M† |
| Share buybacks | – | – | – | $0† | $0† | $0† | $0 | $0† |
| Investing cash flow | $4.83M† | $14.4M† | $191.1M | -$8.04M† | -$6.68M† | $27.5M† | $14.6M | $25.7M† |
| Financing cash flow | -$598.0K† | -$138.0K† | -$40.0K | $620.0K† | -$112.0K† | $108.0K† | -$46.0K | -$54.5M† |
| Net change in cash | -$2.55M† | $4.25M† | $144.6M | -$8.71M† | -$29.2M† | $7.73M† | -$15.3M | -$43.1M† |
| Ratio | ||||||||
| Stock-based compensation, % of revenue | 19.2% | 20.1% | 41.7% | 24.1% | 43.3% | 29.3% | 22.1% | 16.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 1, 2026 | 394.8M | +2.7% | SEC |
| Aug 3, 2026 | 392.6M | +2.8% | SEC |
| Mar 12, 2026 | 390.1M | +2.9% | SEC |
| Nov 2, 2025 | 384.6M | +3.3% | SEC |
| Aug 15, 2025 | 382.0M | +2.9% | SEC |
| May 1, 2025 | 379.8M | +2.1% | SEC |
| Mar 2, 2025 | 379.0M | +30.6% | SEC |
| Nov 1, 2024 | 372.3M | +368.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- Values marked † are derived: Q4 is the full year minus the first three quarters, single-quarter cash flows are year-to-date figures minus the previous year-to-date figures, and the Q4 balance sheet is the year-end balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.